slotkoers
Korea S.E.
00:00:00 10-06-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
31.400
KRW
|
+5,55%
|
|
-0,63%
|
0,00%
|
Fiscaal tijdperk: december |
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
13.858
|
14.219
|
16.032
|
28.472
|
EBITDA
1 |
1.461
|
2.380
|
2.695
|
6.241
|
Bedrijfsresultaat (EBIT)
1 |
1.126
|
1.874
|
2.138
|
5.607
|
Operationele Marge
|
8,13%
|
13,18%
|
13,33%
|
19,69%
|
Resultaat voor belastingen (EBT)
1 |
1.476
|
1.594
|
2.247
|
5.572
|
Nettowinst (verlies)
1 |
1.475
|
1.623
|
2.121
|
4.844
|
Nettomarge
|
10,65%
|
11,42%
|
13,23%
|
17,01%
|
WPA
2 |
23.854
|
26.241
|
31.434
|
978,3
|
Free Cash Flow
|
-
|
1.534
|
153,5
|
-752,5
|
FCF-marge
|
-
|
10,79%
|
0,96%
|
-2,64%
|
Kasstroomconversie (ebitda)
|
-
|
64,44%
|
5,7%
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
94,5%
|
7,24%
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
4.000
|
Datum van publicatie
|
11/04/22
|
11/04/22
|
6/04/23
|
27/03/24
|
Fiscaal tijdperk: december |
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
2.443
|
324
|
-
|
-
|
Nettokaspositie
1 |
-
|
-
|
509
|
3.156
|
Hefboom (schuld/ebitda)
|
1,672
x
|
0,1362
x
|
-
|
-
|
Free Cash Flow
|
-
|
1.534
|
154
|
-752
|
ROE (netto-inkomsten/eigen vermogen)
|
-
|
20,1%
|
21,1%
|
33,4%
|
ROA (netto-inkomsten/totale activa)
|
-
|
7,97%
|
7,91%
|
17,7%
|
Totale activa
1 |
-
|
20.374
|
26.826
|
27.389
|
Nettoactief per aandeel
2 |
117.233
|
143.350
|
174.115
|
3.533
|
Cashflow per aandeel
2 |
41.980
|
71.705
|
59.898
|
777,0
|
Capex
1 |
1.865
|
799
|
180
|
1.369
|
Capex/omzet
|
13,46%
|
5,62%
|
1,12%
|
4,81%
|
Datum van publicatie
|
11/04/22
|
11/04/22
|
6/04/23
|
27/03/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| 0,00% | 127 mln. | | -0,38% | 92,26 mld. | | -3,16% | 38,11 mld. | | +64,83% | 26,51 mld. | | -13,98% | 15,75 mld. | | -5,40% | 13,36 mld. | | -11,38% | 11,65 mld. | | +156,85% | 9,78 mld. | | -49,84% | 10,12 mld. | | +2,32% | 8,84 mld. |
Biofarmaceutica
|